Sign In
NASDAQ:GLPG
Galapagos NV Stock Earnings Reports
$25.49
+0.520 (+2.08%)
At Close: Feb 13, 2025
Galapagos NV Earnings Calls
Q4 2024
(Upcoming)
| Release date | Feb 28, 2025 |
| EPS estimate | -$0.240 |
| EPS actual | - |
| Revenue estimate | 72.541M |
| Revenue actual | - |
| Expected change | +/- 2.61% |
Q3 2024
Missed
-$0.770 (-185.19%)
| Release date | Oct 30, 2024 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.770 |
| EPS Surprise | -185.19% |
| Revenue estimate | 78.211M |
| Revenue actual | 66.85M |
| Revenue Surprise | -14.53% |
Q2 2024
Beat
$0.140 (450.10%)
| Release date | Sep 26, 2024 |
| EPS estimate | $0.0255 |
| EPS actual | $0.140 |
| EPS Surprise | 450.10% |
| Revenue estimate | 76.527M |
| Revenue actual | 83.732M |
| Revenue Surprise | 9.42% |
Q1 2024
Beat
$0.390 (425.00%)
| Release date | May 02, 2024 |
| EPS estimate | -$0.120 |
| EPS actual | $0.390 |
| EPS Surprise | 425.00% |
| Revenue estimate | 75.32M |
| Revenue actual | 67.069M |
| Revenue Surprise | -10.95% |
Last 4 Quarters for Galapagos NV
Below you can see how GLPG performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Beat
| Release date | May 02, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $29.45 |
| EPS estimate | -$0.120 |
| EPS actual | $0.390 |
| EPS surprise | 425.00% |
| Date | Price |
|---|---|
| Apr 26, 2024 | $28.76 |
| Apr 29, 2024 | $28.65 |
| Apr 30, 2024 | $28.45 |
| May 01, 2024 | $29.34 |
| May 02, 2024 | $29.45 |
| May 03, 2024 | $29.09 |
| May 06, 2024 | $29.47 |
| May 07, 2024 | $29.08 |
| May 08, 2024 | $29.03 |
| 4 days before | 2.40% |
| 4 days after | -1.43% |
| On release day | -1.22% |
| Change in period | 0.94% |
Q2 2024
Beat
| Release date | Sep 26, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $29.43 |
| EPS estimate | $0.0255 |
| EPS actual | $0.140 |
| EPS surprise | 450.10% |
| Date | Price |
|---|---|
| Sep 20, 2024 | $29.80 |
| Sep 23, 2024 | $29.27 |
| Sep 24, 2024 | $28.85 |
| Sep 25, 2024 | $28.54 |
| Sep 26, 2024 | $29.43 |
| Sep 27, 2024 | $29.28 |
| Sep 30, 2024 | $28.79 |
| Oct 01, 2024 | $28.50 |
| Oct 02, 2024 | $28.37 |
| 4 days before | -1.24% |
| 4 days after | -3.60% |
| On release day | -0.510% |
| Change in period | -4.80% |
Q3 2024
Missed
| Release date | Oct 30, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $28.59 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.770 |
| EPS surprise | -185.19% |
| Date | Price |
|---|---|
| Oct 24, 2024 | $29.43 |
| Oct 25, 2024 | $28.95 |
| Oct 28, 2024 | $28.76 |
| Oct 29, 2024 | $28.54 |
| Oct 30, 2024 | $28.59 |
| Oct 31, 2024 | $26.44 |
| Nov 01, 2024 | $26.89 |
| Nov 04, 2024 | $26.71 |
| Nov 05, 2024 | $26.74 |
| 4 days before | -2.85% |
| 4 days after | -6.47% |
| On release day | -7.52% |
| Change in period | -9.14% |
Q4 2024
(Upcoming)
| Release date | Feb 28, 2025 |
| Fiscal end date | Dec 30, 2024 |
| Price on release | - |
| EPS estimate | -$0.240 |
| EPS actual | - |
| Date | Price |
|---|---|
| Feb 07, 2025 | $22.78 |
| Feb 10, 2025 | $22.99 |
| Feb 11, 2025 | $23.29 |
| Feb 12, 2025 | $24.97 |
| Feb 13, 2025 | $25.49 |
Galapagos NV Earnings Call Transcript Summary of Q3 2024
- Company Strategy and Positioning:
- Galapagos is focusing on being a pure-play biotech with a renewed research and development (R&D) strategy aimed at accelerating the development and delivery of innovative medicines, particularly in oncology and immunology.
- The company has a strong R&D pipeline, currently comprising four clinical candidates for 11 indications and over 15 preclinical programs.
- Financial Performance:
- Galapagos reported a stable revenue for Q3 2024, primarily from a collaboration with Gilead.
- Significant R&D cost increases were noted, stemming from investments in oncology and collaborations with BridGene and Adaptimmune.
- The company had a net profit of EUR 49 million for the first nine months of 2024, bolstered by fair value adjustments and interest income.
- The cash position at the end of Q3 2024 was EUR 3.3 billion, aligning with the anticipated cash burn of EUR 370 million to EUR 410 million for the year.
- Regulatory Achievements:
- Received FDA clearance for the IND application of GLPG5101 for non-Hodgkin lymphoma, allowing for patient enrollment in the U.S. before year-end.
- Recruitment has resumed for the GLPG5301 Phase I/II study in multiple myeloma.
- A decentralized CAR-T cell therapy manufacturing process was approved, set to enhance the delivery of therapies.
- Pipeline Developments:
- Ongoing enrollment in the GLPG3667 Phase II studies in dermatomyositis and lupus, with topline data expected in 2025-2026.
- Two early-stage pipeline candidates were selected for clinical development.
- Collaboration with Adaptimmune to explore TCR T cell therapies targeting head and neck cancer.
- Data for GLPG5101 and GLPG5201 will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting in December.
- Future Outlook:
- Plans to initiate at least four IND or CTA-enabling studies in 2025 and launch two new clinical assets per year from 2026 onward.
- Expansion of clinical sites and manufacturing capabilities in the U.S. with partnerships (e.g., Blood Centers of America).
- Business Development Focus:
- Active exploration of partnerships and collaborations to expand the company's portfolio in oncology and immunology.
- Emphasis on acquiring clinical assets that target unmet medical needs and have the potential for accelerated development.
- Galapagos is building a strong foundational position with a significant cash reserve, positioning itself for continued growth through R&D and strategic collaborations.
- Recent regulatory achievements and positive clinical developments suggest a positive outlook for the company’s near-term prospects.
- Monitoring the pipeline advancements and financial performance in the upcoming quarters will be crucial for assessing investment potential.
- Investors should watch for upcoming data presentations at ASH and further developments in the clinical pipeline and business partnerships.
- The next earnings call is scheduled for February 13, 2025, to review the full-year results.
Galapagos NV Earnings History
Earnings Calendar
FAQ
When is the earnings report for GLPG?
Galapagos NV (GLPG) has scheduled its earnings report for Feb 28, 2025 after the markets close.
What is the GLPG price-to-earnings (P/E) ratio?
GLPG P/E ratio as of Feb 13, 2025 (TTM) is 7.35.
What is the GLPG EPS forecast?
The forecasted EPS (Earnings Per Share) for Galapagos NV (GLPG) for the first fiscal quarter 2024 is -$0.240.
What are Galapagos NV's retained earnings?
On its balance sheet, Galapagos NV reported retained earnings of $66.85 million for the latest quarter ending Sep 30, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
